Condition: Cholangiocarcinoma · Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
This study aims to validate the efficacy and safety of GP/GEMOX combined with PD-1/L1 inhibitors and TKI agents in patients with advanced cholangiocarcinoma through a multicenter, retrospective study to guide clinical practice.
This description comes directly from the study's public registry record.
Weilin Wang, PHD · +86 057187783820 · wam@zju.edu.cn
Yuan Ding, PHD · +86 18858101960 · dingyuan@zju.edu
Always discuss trial participation with your own doctor first.
| 2nd Affiliated Hospital, School of Medicine, Zhejiang University | Hangzhou, Zhejiang, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06718257